Verici Dx PLC Result of AGM (4438E)
30 June 2023 - 1:57AM
UK Regulatory
TIDMVRCI
RNS Number : 4438E
Verici Dx PLC
29 June 2023
Verici Dx plc
("Verici Dx" or the "Company")
Result of AGM and voting results
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that at the Annual
General Meeting ("AGM") held earlier today, all resolutions were
duly passed.
The voting results of the AGM were as follows:
In Favour Against Withheld
Resolution Votes % Votes % Votes
----------- ---- ------ ----------
1 58,326,878 100 10 0 0
----------- ---- ------ ----------
2 58,326,301 100 587 0 0
----------- ---- ------ ----------
3 57,252,764 100 10 0 1,074,114
----------- ---- ------ ----------
4 57,252,187 100 587 0 1,074,114
----------- ---- ------ ----------
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser Tel: +44 20 7496 3000
& Broker)
Aubrey Powell / Sam Butcher
Walbrook PR Limited Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Stephanie Cuthbert / Mob: +44 7980 541 893 / +44 7796
Sam Allen 794 663 /
07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of
leading-edge tests forming a kidney transplant platform for
personalised patient and organ response risk to assist clinicians
in medical management for improved patient outcomes. The underlying
technology is based upon artificial intelligence assisted
transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for
transplant prognosis of risk of injury, rejection and graft failure
from pre-transplant to late stage. The Company also has a mission
to accelerate the pace of innovation by research using the fully
characterised data from the underlying technology and collaboration
with medical device, biopharmaceutical and data science
partners.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
Verici Dx's two lead products are Tutivia(TM), a post-transplant
test focused upon acute cellular rejection, including sub-clinical
rejection and Clarava(TM), a pre-transplant prognosis test for the
risk of early acute rejection. These products seek to measure how a
patient is likely to respond, and is responding, to a kidney
transplant. These products are underpinned by extensive patented
and published scientific research from the leading Mount Sinai
Medical Center, for which the Company holds an exclusive worldwide
licence.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBUGDLSUDDGXC
(END) Dow Jones Newswires
June 29, 2023 11:57 ET (15:57 GMT)
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Feb 2024 to Feb 2025
